|
Gender
|
|
Female
|
28 (38.4%)
|
42 (36.5)
|
0.80
|
|
Male
|
45 (61.6%)
|
73 (63.5%)
| |
|
Age
|
67 (29–95)
|
63 (37–92)
|
0.26
|
|
Age class (years)
|
|
29–59
|
25 (34.2%)
|
47 (40.9%)
|
0.44
|
|
≥ 60
|
48 (65.8%)
|
68 (59.1%)
| |
|
Clinical outcome
|
|
Mortality
|
15 (20.5%)
|
4 (3.5%)
|
0.0002
|
|
Mortality by gender
|
|
Female
|
9 (81.8%)
|
2 (50%)
|
1
|
|
Male
|
6 (75.0%)
|
2 (50%)
| |
|
Mortality by age class
|
|
29–59
|
1 (6.7%)
|
0 (0%)
| |
|
≥ 60
|
14 (19.18%)
|
4 (3.48%)
|
0.0006
|
|
Comorbidities
|
|
Obesity
|
11 (15.1%)
|
20 (17.4%)
|
0.26
|
|
Cardiopathy
|
19 (26.0%)
|
22 (19.1%)
|
0.28
|
|
Hypertension
|
57 (78.1%)
|
68 (59.1%)
|
0.007
|
|
COPD/pneumonia
|
8 (11.0%)
|
9 (7.8%)
|
0.46
|
|
Smoking/former smoking
|
4 (5.5%)
|
11(9.6%)
|
0.41
|
|
Neurological disease
|
7 (9.6%)
|
6 (5.2%)
|
0.25
|
|
CKD
|
9 (12.3%)
|
2 (1.7%)
|
0.004
|
|
Thyroid
|
9 (12.3%)
|
15 (13%)
|
0.89
|
|
Dyslipidemia
|
33 (45.2%)
|
37 (32.2%)
|
0.07
|
|
Neoplasia/immuno
|
5 (6.8%)
|
7 (6.1%)
|
0.83
|
|
Asthma
|
1 (1.4%)
|
3 (2.6%)
|
0.56
|
|
BMI
|
29.42 ± 5.14
|
29.24 ± 5.28
|
0.16
|
|
In-hospital clinical characteristics
|
|
NEWS
|
2 (0–11)
|
2 (0–9.3)
|
0.63
|
|
Time of stay in ICU
|
3 (0–94)
|
2 (0–41)
|
0.27
|
|
Time of stay in nursery
|
6 (0–39)
|
7 (0–58)
|
0.54
|
|
Total hospitalization time
|
10 (3–100)
|
11 (2–65)
|
0.57
|
|
Time of MV
|
0.0 (0–63);
|
0.0 (0–26)
|
0.09
|
|
In-hospital metformin therapy
|
–
|
115 (100%)
|
–
|
|
In-hospital max dose of metformin
|
–
|
1249.13 ± 578.7
|
–
|
|
In-hospital time of metformin therapy
|
–
|
8.87 ± 9.24;
|
–
|
|
Pre-hospital metformin therapy
|
19 (26%)
|
97 (84.3%)
|
0.000
|
|
Pre-hospital metformin daily dose
|
1235.3 ± 597.22
|
1127.01 ± 629.21
|
0.51
|
|
In-hospital insulin therapy
|
18 (24.7%)
|
43 (37.4%)
|
0.08
|
|
In-hospital time of insulin therapya
|
15.5 (1–98)
|
3 (1–42)
|
0.019
|
|
Orotracheal intubation
|
20 (27.4%)
|
25 (22.5%)
|
0.45
|
|
Prisma
|
11 (15.1%)
|
4 (3.6%)
|
0.011
|
|
Prone
|
4 (5.5%)
|
3 (2.7%)
|
0.4
|
|
Vasoactive drugs
|
19 (26%)
|
18 16.2%
|
0.1
|
|
CLHO/HCQ
|
12 (16.9%)
|
13 (11.3%)
|
0.27
|
|
Dexamethasone/prednisolone
|
65 (89.0%)
|
104 (90.4%)
|
0.75
|
